WHO WE HELP
-
Pharmaceutical Manufacturers
-
MedTech
-
Emerging Biopharma
-
Financial Institutions
-
Government and Public Health
-
Health Plans
-
Hospital and Health Systems
-
Insurers and Risk
-
Medical Specialties
-
Patient Organizations
Pharmaceutical Manufacturers
Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Discover MorePharmaceutical Manufacturers
MedTech
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechMedTech
Emerging Biopharma (Global page)
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover Innovations
Financial Institutions
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsGovernment and Public Health
Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsGovernment and Public Health
Health Plans
Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansHospital and Health Systems
Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsHospital and Health Systems
Insurers and Risk
Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Uncover More
Medical Specialties
Embrace digital innovation in healthcare and transform your organization with a suite of cutting-edge registry solutions.
EXPLORE SOLUTIONS
Patient Organizations
Maximize your patient impact with expert guidance, data-driven insights, and a suite of cutting-edge patient data solutions.
DRIVE PATIENT IMPACTU.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
PODCASTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTS
Webinar
"Collaborative Intelligence: Empowering the Human-AI Workforce in Life Sciences
REGISTER NOW
Video
Patient Behavior Insight Express
Get smart fast with our Thought Leadership video blog series
Sep 25, 2025
Insight Express: Your FAST Insight
IQVIA experts explore a new industry hot topic in under two minutes
Insight Express Series 1: Patient Behavior | Abandonment
When patients face higher out-of-pocket costs, they are less likely to fill their prescriptions. This trend is consistent across all brands, therapeutic classes, and payer channels. If a patient does not fill a payer-approved prescription, it is considered abandoned. This behavior influences insurers' benefit designs, access contracts, and demand capture strategies, and is a key consideration for policymakers aiming to assist patients.
Insight Express Series 1: Patient Behavior | Adherence
As patients' out-of-pocket costs rise, their likelihood of continuing therapy in the first year (i.e., adherence) declines. This relationship holds across different diseases, products, and patient types. Factors such as competing therapies, patient demographics, support programs, and annual out-of-pocket caps, like Medicare Part D’s $2,000 max, all contribute to shaping patient adherence.
Insight Express Series 1: Patient Behavior | One and Done
Persistence measures how long a patient continues a prescription, while “One and Done” describes those who fill only once and do not return. This can stem from price concerns, side effects, other health issues, dosing, effectiveness, demographics, or insurance coverage. Securing the initial fill is costly, but ensuring patients continue therapy is essential for better outcomes and accurate forecasting. If patients stop treatment early, they miss the potential benefits of therapy.
Insight Express Series 1: Patient Behavior | Medicare Part D $2000 Cap
Big changes are coming to Medicare Part D. Following the removal of catastrophic phase cost-sharing in 2024, a new $2,000 annual out-of-pocket cap takes effect in 2025. This major policy shift has the potential to reshape patient behavior as the reduced financial burden are expected to reduce prescription abandonment, improve treatment initiation rates, and enhance long-term adherence.
Insight Express Series 1: Patient Behavior | Medicare Part D: Patients with $0 Copay
How is the $2,000 Medicare Part D cap that began this year reshaping speciality treatment access? Dive deeper into its impact on oncology with trends from recent years as changes from the Inflation Reduction Act took effect. Patients are seeing improved access, but the ripple effects matter for other key stakeholders, too.